Clinical Trials Logo

Blood Disorder clinical trials

View clinical trials related to Blood Disorder.

Filter by:
  • None
  • Page 1

NCT ID: NCT03520712 Active, not recruiting - Hemophilia A Clinical Trials

Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5

GENEr8-AAV5+
Start date: April 3, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being conducted by BioMarin Pharmaceutical Inc. as an open label, single dose study to determine the safety of valoctocogene roxaparvovec (an Adenovirus-Associated Virus (AAV) based gene therapy vector) in severe Hemophilia A patients with pre-existing antibodies against AAV5.

NCT ID: NCT03518294 Completed - Liver Diseases Clinical Trials

NASH Fitness Intervention in Thrombosis Trial (NASHFit)

Start date: June 1, 2018
Phase: N/A
Study type: Interventional

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in the United States. The most advanced forms of NAFLD are associated with increased liver-related mortality and lower overall survival. The current standard of care for NAFLD is lifestyle changes through diet and exercise. The human genome and regulation of gene expression is influenced by physical activity. NAFLD is a prothrombotic state with derangements in all three phases of hemostasis leading to clinically important clotting events. Exercise can improve coagulation in healthy persons. In this proposal, we seek to begin a line of work to answer the question "Can lifestyle changes effectively mitigate the increased risk of clotting in patients with NAFLD?" focusing initially on the at-risk population genetically susceptible to advanced disease.

NCT ID: NCT03176849 Completed - Clinical trials for Myelodysplastic Syndromes

A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT

Start date: November 1, 2017
Phase: Phase 4
Study type: Interventional

Research has suggested that children with sufficient vitamin D levels undergoing hematopoietic stem cell transplant (HSCT) have improved outcomes, including lower incidences of infection and graft-versus-host disease (GVHD), as well as overall improved survival. However, supplementation in children undergoing HSCT has shown to be a challenge using standard or aggressive supplementation strategies. The primary objective of this study is to determine the safety and efficacy of a single, high dose oral vitamin D (Stoss Therapy) at the start of transplant followed by maintenance supplementation in children undergoing HSCT.